Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy of Blink Tears and Systane used concomitantly with topical cyclosporine for the treatment of dry eye.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Dry eye is a chronic condition that is believed to afflict more than 3 million patients in the United States.1 Symptoms of dry eye are very bothersome and impact quality of life, reduce work capacity, and may result in poorer psychological health. Also, symptoms of dry eye are associated with a decreased ability to perform activities that require visual attention such as reading and driving a car.2 Patients with dry eye complain most frequently of a scratchy or sandy (foreign body) sensation. Other common symptoms are itching, excessive mucus secretion, inability to produce tears, a burning sensation, photosensitivity, redness, pain, and difficulty in moving the lids. In most patients, the most remarkable feature of the eye examination is the grossly normal appearance of the eye.3 Chronic dry eye disease is associated with an inflammatory mechanism mediated by activated T-cell lymphocytes3 which affects the ocular surface and lacrimal gland.4 The damage caused by dry eye disease may be irreversible, and despite the availability of various tear substitutes, many patients with dry eye syndrome experience corneal injuries with a subsequent reduction in vision.5 Cyclosporin A (Restasis®, Allergan, Irvine, CA) has been shown to significantly reduce the number of activated T-lymphocytes within the conjunctiva6, thereby minimizing the inflammation causing dry eye. Topical cyclosporin A 0.05% ophthalmic emulsion (Restasis®, Allergan, Irvine, CA) increases tear production and improves the quality of naturally produced tears and is the first approved therapeutic agent for the treatment of chronic dry eye and the only treatment modality that addresses the underlying pathology.
In addition to topical therapy with cyclosporine, some patients continue to use artificial tears for occasional relief of residual symptoms. The choice of concomitant tear is important but little research has been published differentiating between the efficacy of these solutions when used concomitantly with topical cyclosporine.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Blink Tears
|
Drug: Cyclosporin A Restasis®
Drug: Blink tears
blink tears to be used twice a day
|
| Experimental: Systane
|
Drug: Cyclosporin A Restasis®
Drug: Systane
systane to be used twice a day
|
Outcome Measures
Primary Outcome Measures
- Change in Schirmer's Scores [baseline to 3 months]
The Schirmer score is a score on a scale - minimum is 0 and the highest is 35 mm. Above 15 mm is normal and less than 5 is severe dry eyes. A positive score means there was an improvement, 0 will be no change from baseline and a negative one that there was a decreased in tears. This change was calculated by subtracting the baseline value from the 3 months value (3 mo Schirmer's - baseline Schirmer's = amount of change).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject must have dry eye.
-
Age: 18 years and older.
-
Males or females
-
Up to grade 3 conjunctival staining.
-
Score of no more than 4 on the Subjective Evaluation of Symptoms of Dryness (SESOD) at screening.
-
Currently using Restasis to treat dry eye syndrome (at least for 3 months prior to enrollment).
-
Willing and able to comply with scheduled visits and other study procedures.
Exclusion Criteria:
-
Prior unsuccessful use of topical cyclosporine (defined as patients taking it at least 3 months without improvement.
-
Known contraindications to any study medication or ingredients.
-
Planned use of contact lenses (unless discontinued use more than 30 days prior to randomization.
-
Contact lens use during the active treatment portion of the trial.
-
Active ocular allergies.
-
Ocular surgery within the past 3 months.
-
Any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis.
-
Active ocular diseases or uncontrolled systemic disease (blepharitis patients that are actively being treated or disease that is uncontrollable.
-
Pregnant or nursing mothers and females of childbearing potential not practicing a reliable and medically acceptable method of birth control.
-
Participation in (or current participation) any investigational drug or device trial.
-
Conjuctival staining grade 4.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Medical University of South Carolina, Storm Eye Institute | Charleston | South Carolina | United States | 29425 |
Sponsors and Collaborators
- Medical University of South Carolina
Investigators
- Principal Investigator: Kerry D. Solomon, MD, Medical University of South Carolina, Storm Eye Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SEI-07-003
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Blink Tears | Systane |
|---|---|---|
| Arm/Group Description | ||
| Period Title: Overall Study | ||
| STARTED | 11 | 9 |
| COMPLETED | 11 | 9 |
| NOT COMPLETED | 0 | 0 |
Baseline Characteristics
| Arm/Group Title | Blink Tears | Systane | Total |
|---|---|---|---|
| Arm/Group Description | Total of all reporting groups | ||
| Overall Participants | 11 | 9 | 20 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
66.3
(9.7)
|
67.4
(7.82)
|
66.8
(8.8)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
10
90.9%
|
9
100%
|
19
95%
|
| Male |
1
9.1%
|
0
0%
|
1
5%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |||
| Hispanic or Latino |
0
0%
|
0
0%
|
0
0%
|
| Not Hispanic or Latino |
11
100%
|
9
100%
|
20
100%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
| Race (NIH/OMB) (Count of Participants) | |||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
| Asian |
0
0%
|
0
0%
|
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
0
0%
|
0
0%
|
0
0%
|
| White |
11
100%
|
9
100%
|
20
100%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
| Region of Enrollment (Count of Participants) | |||
| United States |
11
100%
|
9
100%
|
20
100%
|
Outcome Measures
| Title | Change in Schirmer's Scores |
|---|---|
| Description | The Schirmer score is a score on a scale - minimum is 0 and the highest is 35 mm. Above 15 mm is normal and less than 5 is severe dry eyes. A positive score means there was an improvement, 0 will be no change from baseline and a negative one that there was a decreased in tears. This change was calculated by subtracting the baseline value from the 3 months value (3 mo Schirmer's - baseline Schirmer's = amount of change). |
| Time Frame | baseline to 3 months |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | Blink Tears | Systane |
|---|---|---|
| Arm/Group Description | ||
| Measure Participants | 11 | 9 |
| Mean (Standard Error) [score on a scale] |
-.30
(2.82)
|
-1.06
(4.17)
|
Adverse Events
| Time Frame | ||||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Blink Years | Systane | ||
| Arm/Group Description | ||||
All Cause Mortality |
||||
| Blink Years | Systane | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Blink Years | Systane | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/11 (0%) | 0/9 (0%) | ||
Other (Not Including Serious) Adverse Events |
||||
| Blink Years | Systane | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/11 (0%) | 0/9 (0%) | ||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Helga Sandoval |
|---|---|
| Organization | Carolina Eye |
| Phone | |
| hps@cepmd.com |
- SEI-07-003